Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 10/20 | 0.62 |
| ▸ | NAMPT | P43490 | 7/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21424078 | 0.83 | PANK3 (0.62) | PANK3NAMPTTRPV1 | |
| SCHEMBL19748764 | 0.83 | PANK3 (0.62) | PANK3NAMPT | |
| SCHEMBL13203001 | 0.81 | PANK3 (0.59) | PANK3NAMPTTRPV1 | |
| SCHEMBL12489502 | 0.78 | CHRM1 (0.52) | NAMPT | |
| SCHEMBL19747977 | 0.77 | PANK3 (1.00) | PANK3 | |
| SCHEMBL21406301 | 0.74 | PANK3 (0.92) | PANK3 | |
| SCHEMBL29980676 | 0.74 | GRM1 (0.53) | NAMPT | |
| SCHEMBL12686706 | 0.74 | GRM1 (0.53) | NAMPT | |
| SCHEMBL6764626 | 0.73 | TRPV1 (0.60) | PANK3TRPV1 | |
| SCHEMBL6764530 | 0.73 | NAMPT (0.54) | PANK3NAMPTTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11547709-B2 | Methods of treating disorders associated with castor | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210246113-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2021-08-12 | — | — | US | disclosed |
| US-20210023081-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11547709-B2 | Methods of treating disorders associated with castor | HMGCR, GCDH, CYP11A1 | PANK3 1573/4885NAMPT 574/4885TRPV1 4795/4885 |
| US-20210246113-A1 | SMALL MOLECULE MODULATORS OF PANTOTHENATE KINASES | PANK2, PANK1, PANK3 | PANK3 3/4885NAMPT 17/4885TRPV1 1386/4885 |
| US-20210023081-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | HMGCR, GCDH, CYP11A1 | PANK3 1573/4885NAMPT 574/4885TRPV1 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.